Soleno Therapeutics, Inc.
SLNO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $79 | $25 | $15 | $21 |
| G&A Expenses | $106 | $13 | $10 | $11 |
| SG&A Expenses | $106 | $13 | $10 | $11 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $3 | $3 | -$1 | -$1 |
| Operating Expenses | $188 | $41 | $24 | $32 |
| Operating Income | -$188 | -$41 | -$24 | -$32 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $12 | $2 | $0 | $1 |
| Pre-Tax Income | -$176 | -$39 | -$24 | -$31 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$176 | -$39 | -$24 | -$31 |
| % Margin | – | – | – | – |
| EPS | -4.38 | -2.36 | -2.87 | -5.81 |
| % Growth | -85.6% | 17.8% | 50.6% | – |
| EPS Diluted | -4.38 | -2.36 | -2.87 | -5.81 |
| Weighted Avg Shares Out | 40 | 16 | 8 | 5 |
| Weighted Avg Shares Out Dil | 40 | 16 | 8 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $12 | $3 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $2 | $2 | $2 |
| EBITDA | -$174 | -$37 | -$22 | -$30 |
| % Margin | – | – | – | – |